<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Organisms : Viruses : RNA viruses : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Biology and life sciences : Microbiology"/>
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Flaviviruses : Hepacivirus: Hepatitis C virus :"/>
 <result pre=": Microbial pathogens : Viral pathogens : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Medicine and health sciences : Pathology"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Flaviviruses : Hepacivirus: Hepatitis C virus :"/>
 <result pre=": Microbial pathogens : Viral pathogens : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Biology and life sciences : Organisms"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Flaviviruses : Hepacivirus: Hepatitis C virus :"/>
 <result pre="Organisms : Viruses : Viral pathogens : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Biology and life sciences : Microbiology"/>
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis C virus : Medicine"/>
 <result pre=": Medical microbiology : Microbial pathogens : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis C virus : Medicine and health sciences"/>
 <result pre="microbiology : Microbial pathogens : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="C virus : Medicine and health sciences : Pathology"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis C virus : Biology"/>
 <result pre="medicine : Pathogens : Microbial pathogens : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis C virus : Biology and life sciences"/>
 <result pre="Pathogens : Microbial pathogens : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="C virus : Biology and life sciences : Organisms"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis C virus : Medicine"/>
 <result pre="life sciences : Organisms : Viruses : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis C virus : Medicine and health sciences"/>
 <result pre=": Organisms : Viruses : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="C virus : Medicine and health sciences : Infectious"/>
 <result pre="viruses: Hepatitis C virus : Medicine and health sciences :" exact="Infectious" post="diseases : Viral diseases : Hepatitis: Hepatitis C :"/>
 <result pre="virus : Medicine and health sciences : Infectious diseases :" exact="Viral" post="diseases : Hepatitis: Hepatitis C : Medicine and health"/>
 <result pre="health sciences : Infectious diseases : Viral diseases : Hepatitis:" exact="Hepatitis" post="C : Medicine and health sciences : Gastroenterology and"/>
 <result pre="health sciences : Gastroenterology and hepatology : Liver diseases :" exact="Infectious" post="hepatitis: Hepatitis C : Biology and Life Sciences :"/>
 <result pre=": Gastroenterology and hepatology : Liver diseases : Infectious hepatitis:" exact="Hepatitis" post="C : Biology and Life Sciences : Immunology :"/>
 <result pre="Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for" exact="Hepatitis" post="C Telaprevir vs. Boceprevir: A Randomized Head-to-Head Trial DavitkovPerica123ChandarApoorva"/>
 <result pre="combination with peginterferon and ribavirin, stratified by the presence of" exact="cirrhosis" post="and prior treatment experience. Tolerability was assessed at each"/>
 <result pre="PI treatment were adjudicated using a blinded adjudication committee. The" exact="primary" post="outcome was difference in tolerability between boceprevir vs. telaprevir."/>
 <result pre="primary outcome was difference in tolerability between boceprevir vs. telaprevir." exact="Secondary" post="outcomes included viral response rates and cost-per cure achieved."/>
 <result pre="difference in tolerability between boceprevir vs. telaprevir. Secondary outcomes included" exact="viral" post="response rates and cost-per cure achieved. Results Higher rates"/>
 <result pre="CI: 0.76, 1.99; p = 0.39). On an intention-to-treat basis," exact="total" post="cost per cure was $44,329 for boceprevir vs. $57,115"/>
 <result pre="severe adverse events leading to treatment discontinuations, hospitalizations or severe" exact="anemia" post="and a substantially higher cost per SVR when compared"/>
 <result pre="Introduction Globally/Worldwide, approximately/about/ 185 million people are infected with the" exact="Hepatitis" post="C virus (HCV).[1, 2] In the United States, between"/>
 <result pre="4] Approximately 5.4% of veterans in the United States have" exact="chronic" post="HCV, which is more than double the estimated prevalence"/>
 <result pre="general US population.[5] Untreated HCV is likely to progress to" exact="liver cirrhosis" post="and is strongly associated with the development of hepatocellular"/>
 <result pre="US population.[5] Untreated HCV is likely to progress to liver" exact="cirrhosis" post="and is strongly associated with the development of hepatocellular"/>
 <result pre="hepatocellular carcinoma.[6–8] The risk of mortality among untreated veterans with" exact="chronic" post="HCV is nearly 25 per 1000 person years.[9] Historically,"/>
 <result pre="translate to similar findings in the clinical setting where much" exact="lower" post="SVR rates were observed.[13] Peg-IFN/RBV combination therapy was also"/>
 <result pre="facilitating decisions in selection between seemingly comparable treatment choices. The" exact="primary" post="objective of this RCT was to compare tolerability of"/>
 <result pre="HCV treatment in treatment naïve and treatment experienced veterans. The" exact="secondary" post="objectives were: a) to evaluate the effectiveness of boceprevir"/>
 <result pre="were stratified based on prior treatment experience and presence or" exact="absence of" post="cirrhosis. There was blinded adjudication of key clinical outcomes."/>
 <result pre="submitted (Clinicaltrials.gov registration: NCT02113631). Patients Patients were recruited from the" exact="hepatitis" post="C outpatient clinic. The trial was conducted as a"/>
 <result pre="inclusion/exclusion criteria identical to current clinical practice. Eligible patients were" exact="adult" post="veterans (≥18 years) with HCV GT1 infection and evidence"/>
 <result pre="Eligible patients were adult veterans (≥18 years) with HCV GT1" exact="infection" post="and evidence of chronic hepatitis. The presence of cirrhosis"/>
 <result pre="veterans (≥18 years) with HCV GT1 infection and evidence of" exact="chronic hepatitis." post="The presence of cirrhosis was confirmed by a liver"/>
 <result pre="GT1 infection and evidence of chronic hepatitis. The presence of" exact="cirrhosis" post="was confirmed by a liver biopsy completed within 3"/>
 <result pre="a liver biopsy was not available, a clinical assessment of" exact="cirrhosis" post="risk was performed by the two independent hepatologists (YFY"/>
 <result pre="creatinine ≤ 1.5 mg/dL; patients needed to demonstrate adequately controlled" exact="diabetes mellitus" post="and normal or adequately controlled TSH on prescription medication."/>
 <result pre="or adequately controlled TSH on prescription medication. Patients with compensated" exact="liver cirrhosis" post="were eligible to participate in the study. Patients who"/>
 <result pre="adequately controlled TSH on prescription medication. Patients with compensated liver" exact="cirrhosis" post="were eligible to participate in the study. Patients who"/>
 <result pre="who were previously treated with Peg-IFN/RBV and were non-responders (NR)," exact="partial" post="responders, or relapsers were also eligible. Exclusion criteria were"/>
 <result pre="information for boceprevir and telaprevir.[15, 16] These included: co-infection with" exact="Hepatitis" post="B Virus (HBV) or Human Immunodeficiency Virus (HIV), severe"/>
 <result pre="These included: co-infection with Hepatitis B Virus (HBV) or Human" exact="Immunodeficiency" post="Virus (HIV), severe unstable neuropsychiatric disorders as determined by"/>
 <result pre="diagnosed and/or treated within the past 3 years (except for" exact="localized" post="squamous or basal cell cancers), and current alcoholism or"/>
 <result pre="(except for localized squamous or basal cell cancers), and current" exact="alcoholism" post="or drug addiction. Treatments Boceprevir and telaprevir were administered"/>
 <result pre="4 weeks of treatment. Prior non-responders or patients with compensated" exact="cirrhosis" post="received boceprevir for 44 weeks and Peg-IFN/RBV for 48"/>
 <result pre="after 4 weeks of treatment. Non-responders and patients with compensated" exact="cirrhosis" post="were prescribed telaprevir for 12 weeks and Peg-IFN/RBV for"/>
 <result pre="p.o. divided twice daily for patients &amp;lt;75kg. Treatment outcomes The" exact="primary" post="endpoint of this trial was tolerability of the DAAs."/>
 <result pre="further decided if the AEs were protease inhibitor (PI) related." exact="Secondary" post="endpoints of the study were: a) achievement of SVR24"/>
 <result pre="telaprevir. Statistical Analysis This study was projected to enroll a" exact="total" post="of 200 subjects (100:100) in groups 1 and 2"/>
 <result pre="an increase of 10% to the sample size was projected." exact="Primary" post="and secondary endpoints were analyzed using the intention-to-treat (ITT)"/>
 <result pre="of 10% to the sample size was projected. Primary and" exact="secondary" post="endpoints were analyzed using the intention-to-treat (ITT) analysis. SVR"/>
 <result pre="with an average age of 59 years. Forty-four percent were" exact="African" post="American, 48% were Caucasian and 4% were Hispanic or"/>
 <result pre="Hispanic or Latino. Liver biopsy results revealed advanced fibrosis or" exact="cirrhosis" post="(F3 and F4) in 10/50 (20%), and 2/50 (4%)"/>
 <result pre="and F4) in 10/50 (20%), and 2/50 (4%) patients had" exact="cirrhosis" post="determined with clinical assessment by the two independent hepatologists."/>
 <result pre="(8) Gender [n (%)]  • Male 25 (100) 24 (96)" exact="Advanced" post="fibrosis (3/4) or cirrhosis [n (%)] 6 (24) 6"/>
 <result pre=" • Male 25 (100) 24 (96) Advanced fibrosis (3/4) or" exact="cirrhosis" post="[n (%)] 6 (24) 6 (24) Treatment exposure [n"/>
 <result pre="hospitalization due to progressive maculopapular rash, and another developed severe" exact="anemia" post="(Hb ≤8 g/dL). Of the two patients on boceprevir"/>
 <result pre="(32) 0.04  • Hospitalization 0 (0) 1 (4) 0.77  •" exact="Severe" post="anemia (&amp;lt;8 g/dL) 0 (0) 1 (4) 0.77  •"/>
 <result pre="0.04  • Hospitalization 0 (0) 1 (4) 0.77  • Severe" exact="anemia" post="(&amp;lt;8 g/dL) 0 (0) 1 (4) 0.77  • Total"/>
 <result pre="Severe anemia (&amp;lt;8 g/dL) 0 (0) 1 (4) 0.77  •" exact="Total" post="2 (8) 10 (40) &amp;lt;0.01 AEs due to Peg-IFN/RBV"/>
 <result pre="vomiting and flu-like symptoms 2 (8) 0 (0) 0.43 *Toxicity:" exact="Severe" post="rash, rectal burning/ pruritus, and dysguesia, PI: Protease Inhibitor;"/>
 <result pre="with cirrhosis) 7/16 8/16 0.9 (0.5–1.6) 0.35 Treatment experienced [partial" exact="viral" post="responders, non-responders and relapsers] (n = 18; 22% with"/>
 <result pre="= 18; 22% with cirrhosis) 4/9 4/9 1 (0.3–3.1) 0.5" exact="Total" post="(n = 50; 24% with cirrhosis) 11/25 12/25 1.07"/>
 <result pre="on boceprevir (8%) and 1 patient on telaprevir (4%) experienced" exact="viral" post="relapse between weeks 4 and 12 after completion of"/>
 <result pre="were considered to have met the futility criteria due to" exact="viral" post="breakthrough or non-response. Resource use Patients in the boceprevir"/>
 <result pre="and 2 patients were briefly hospitalized. On an ITT basis," exact="total" post="cost per SVR achieved was $44,329 for boceprevir vs."/>
 <result pre="$31,823.00 $25,168.00  • Routine drugs cost (PI/Peg-IFN/RBV) $440,997.78 $648,884.00  •" exact="Total" post="routine care cost per person $18,912.83 $26,962.08 Additional care"/>
 <result pre=" • Cost of adverse events per study arm $14,801.00 $24,594.00" exact="Total" post="treatment cost per SVR $44,329.25 $57,115.17 *Outpatient evaluation by"/>
 <result pre="two treatment groups, but both telaprevir and boceprevir showed substantially" exact="lower" post="viral cure rates than observed in the registration trials."/>
 <result pre="treatment groups, but both telaprevir and boceprevir showed substantially lower" exact="viral" post="cure rates than observed in the registration trials. Cost"/>
 <result pre="two novel protease inhibitors in 2011 sparked an interest in" exact="hepatitis" post="C treatment. Given the lack of evidence-based guidelines concerning"/>
 <result pre="hepatitis C treatment. Given the lack of evidence-based guidelines concerning" exact="hepatitis" post="C treatment when these drugs were approved, clinicians preferred"/>
 <result pre="been classified as preliminary as they either focused solely on" exact="viral" post="cure and ignored the balance between benefits and harms"/>
 <result pre="when drug unit costs are high. Most (~93%) veterans with" exact="chronic" post="HCV in Veterans Affairs (VA) care are 50 years"/>
 <result pre="a third are older than 60 years. As a result," exact="hepatitis" post="C is an important disease of aging; especially since"/>
 <result pre="60 years. As a result, hepatitis C is an important" exact="disease" post="of aging; especially since older patients typically have lower"/>
 <result pre="important disease of aging; especially since older patients typically have" exact="lower" post="tolerability thresholds to antivirals. Therefore, we felt it was"/>
 <result pre="significant difference in DAA tolerability was evident, which was our" exact="primary" post="outcome measure. Second, our study was also underpowered to"/>
 <result pre="detect any differences among important sub-populations, such as patients with" exact="cirrhosis" post="or women. Additionally, the FDA approved two new DAAs,"/>
 <result pre="Pragmatic RCTs in the context of the newer generation of" exact="hepatitis" post="C therapies merits discussion. These newer antiviral treatments achieve"/>
 <result pre="cost-simulation data can provide indirect estimates of cost-effectiveness,[31] they are" exact="limited" post="in their use because of lack of real-world cost-effectiveness"/>
 <result pre="sicker and aging population can be particularly useful in guiding" exact="hepatitis" post="C treatment choices. Based on our findings and the"/>
 <result pre="AE Adverse Event CUPIC Compassionate Use of Protease Inhibitors in" exact="Viral" post="C Cirrhosis DAA Direct-acting Antiviral Agents ED Emergency Department"/>
 <result pre="and Drug Administration GCP Good Clinical Practice GT Genotype HBV" exact="Hepatitis" post="B virus HCV Hepatitis C Virus HIV Human Immunodeficiency"/>
 <result pre="Good Clinical Practice GT Genotype HBV Hepatitis B virus HCV" exact="Hepatitis" post="C Virus HIV Human Immunodeficiency Virus IFN Interferon ITT"/>
 <result pre="HBV Hepatitis B virus HCV Hepatitis C Virus HIV Human" exact="Immunodeficiency" post="Virus IFN Interferon ITT Intention-to-treat NR Non-responder PegIFN Pegylated"/>
 <result pre="RBV Ribavirin RCT Randomized Controlled Trial RR Relative Risk SAE" exact="Severe" post="Adverse Event SVR Sustained Virologic Response TSH Thyroid-Stimulating Hormone"/>
 <result pre="References References 1Mohd HanafiahK, GroegerJ, FlaxmanAD, WiersmaST. Global epidemiology of" exact="hepatitis" post="C virus infection: new estimates of age-specific antibody to"/>
 <result pre="Guidelines for the screening, care and treatment of persons with" exact="hepatitis" post="C infection. World Health Organization Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL,"/>
 <result pre="http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ 3ArmstrongGL, WasleyA, SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The prevalence of" exact="hepatitis" post="C virus infection in the United States, 1999 through"/>
 <result pre="WasleyA, SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The prevalence of hepatitis C" exact="virus infection" post="in the United States, 1999 through 2002. Annals of"/>
 <result pre="SimardEP, McQuillanGM, KuhnertWL, AlterMJ. The prevalence of hepatitis C virus" exact="infection" post="in the United States, 1999 through 2002. Annals of"/>
 <result pre="2006;144(10):705–14. .16702586 4DennistonMM, JilesRB, DrobeniucJ, KlevensRM, WardJW, McQuillanGM, et al.Chronic" exact="hepatitis" post="C virus infection in the United States, National Health"/>
 <result pre="4DennistonMM, JilesRB, DrobeniucJ, KlevensRM, WardJW, McQuillanGM, et al.Chronic hepatitis C" exact="virus infection" post="in the United States, National Health and Nutrition Examination"/>
 <result pre="JilesRB, DrobeniucJ, KlevensRM, WardJW, McQuillanGM, et al.Chronic hepatitis C virus" exact="infection" post="in the United States, National Health and Nutrition Examination"/>
 <result pre="5DominitzJA, BoykoEJ, KoepsellTD, HeagertyPJ, MaynardC, SporlederJL, et al.Elevated prevalence of" exact="hepatitis" post="C infection in users of United States veterans medical"/>
 <result pre="KoepsellTD, HeagertyPJ, MaynardC, SporlederJL, et al.Elevated prevalence of hepatitis C" exact="infection" post="in users of United States veterans medical centers. Hepatology."/>
 <result pre="2005;41(1):88–96. 10.1002/hep.20502 .15619249 6PradatP, VoirinN, TillmannHL, ChevallierM, TrepoC. Progression to" exact="cirrhosis" post="in hepatitis C patients: an age-dependent process. Liver international:"/>
 <result pre=".15619249 6PradatP, VoirinN, TillmannHL, ChevallierM, TrepoC. Progression to cirrhosis in" exact="hepatitis" post="C patients: an age-dependent process. Liver international: official journal"/>
 <result pre=".17355454 7SaitoI, MiyamuraT, OhbayashiA, HaradaH, KatayamaT, KikuchiS, et al.Hepatitis C" exact="virus infection" post="is associated with the development of hepatocellular carcinoma. Proceedings"/>
 <result pre="7SaitoI, MiyamuraT, OhbayashiA, HaradaH, KatayamaT, KikuchiS, et al.Hepatitis C virus" exact="infection" post="is associated with the development of hepatocellular carcinoma. Proceedings"/>
 <result pre="al.Hepatitis C virus infection is associated with the development of" exact="hepatocellular carcinoma." post="Proceedings of the National Academy of Sciences of the"/>
 <result pre="BeckettGA, Falck-YtterY, HoltzmanD, TeoCG, et al.Recommendations for the identification of" exact="chronic hepatitis" post="C virus infection among persons born during 1945–1965. MMWR"/>
 <result pre="Falck-YtterY, HoltzmanD, TeoCG, et al.Recommendations for the identification of chronic" exact="hepatitis" post="C virus infection among persons born during 1945–1965. MMWR"/>
 <result pre="TeoCG, et al.Recommendations for the identification of chronic hepatitis C" exact="virus infection" post="among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32."/>
 <result pre="et al.Recommendations for the identification of chronic hepatitis C virus" exact="infection" post="among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32."/>
 <result pre="al.The risk of long-term morbidity and mortality in patients with" exact="chronic hepatitis" post="C: results from an analysis of data from a"/>
 <result pre="risk of long-term morbidity and mortality in patients with chronic" exact="hepatitis" post="C: results from an analysis of data from a"/>
 <result pre="alone or in combination with ribavirin as initial treatment for" exact="chronic hepatitis" post="C. Hepatitis Interventional Therapy Group. The New England journal"/>
 <result pre="or in combination with ribavirin as initial treatment for chronic" exact="hepatitis" post="C. Hepatitis Interventional Therapy Group. The New England journal"/>
 <result pre="combination with ribavirin as initial treatment for chronic hepatitis C." exact="Hepatitis" post="Interventional Therapy Group. The New England journal of medicine."/>
 <result pre="interferon alpha2b plus placebo for 48 weeks for treatment of" exact="chronic" post="infection with hepatitis C virus. International Hepatitis Interventional Therapy"/>
 <result pre="alpha2b plus placebo for 48 weeks for treatment of chronic" exact="infection" post="with hepatitis C virus. International Hepatitis Interventional Therapy Group"/>
 <result pre="placebo for 48 weeks for treatment of chronic infection with" exact="hepatitis" post="C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet."/>
 <result pre="for treatment of chronic infection with hepatitis C virus. International" exact="Hepatitis" post="Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426–32. .9807989 12ZeuzemS, FeinmanSV,"/>
 <result pre="RasenackJ, HeathcoteEJ, LaiMY, GaneE, et al.Peginterferon alfa-2a in patients with" exact="chronic hepatitis" post="C. The New England journal of medicine. 2000;343(23):1666–72. 10.1056/NEJM200012073432301"/>
 <result pre="HeathcoteEJ, LaiMY, GaneE, et al.Peginterferon alfa-2a in patients with chronic" exact="hepatitis" post="C. The New England journal of medicine. 2000;343(23):1666–72. 10.1056/NEJM200012073432301"/>
 <result pre="McCulloughAJ. Surprisingly small effect of antiviral treatment in patients with" exact="hepatitis" post="C. Annals of internal medicine. 2002;136(4):288–92. .11848726 14BrokJ, GluudLL,"/>
 <result pre=".11848726 14BrokJ, GluudLL, GluudC. Ribavirin plus interferon versus interferon for" exact="chronic hepatitis" post="C. The Cochrane database of systematic reviews. 2010;(1):CD00544510.1002/14651858.CD005445.pub2 .20091577"/>
 <result pre="14BrokJ, GluudLL, GluudC. Ribavirin plus interferon versus interferon for chronic" exact="hepatitis" post="C. The Cochrane database of systematic reviews. 2010;(1):CD00544510.1002/14651858.CD005445.pub2 .20091577"/>
 <result pre="DusheikoG, Di BisceglieAM, ReddyKR, BzowejNH, et al.Telaprevir for previously untreated" exact="chronic hepatitis" post="C virus infection. The New England journal of medicine."/>
 <result pre="Di BisceglieAM, ReddyKR, BzowejNH, et al.Telaprevir for previously untreated chronic" exact="hepatitis" post="C virus infection. The New England journal of medicine."/>
 <result pre="ReddyKR, BzowejNH, et al.Telaprevir for previously untreated chronic hepatitis C" exact="virus infection." post="The New England journal of medicine. 2011;364(25):2405–16. 10.1056/NEJMoa1012912 .21696307"/>
 <result pre="18PoordadF, McConeJJr., BaconBR, BrunoS, MannsMP, SulkowskiMS, et al.Boceprevir for untreated" exact="chronic" post="HCV genotype 1 infection. The New England journal of"/>
 <result pre="telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1" exact="infection" post="and cirrhosis. Gastroenterology. 2014;147(1):132–42 e4. 10.1053/j.gastro.2014.03.051 .24704719 20BonnetD, GuivarchM,"/>
 <result pre="al.Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated" exact="hepatitis" post="C virus patients. World journal of hepatology. 2014;6(9):660–9. 10.4254/wjh.v6.i9.66025276282"/>
 <result pre="World journal of hepatology. 2014;6(9):660–9. 10.4254/wjh.v6.i9.66025276282 21SchulzKF, AltmanDG, MoherD, collab:" exact="Group C." post="CONSORT 2010 statement: updated guidelines for reporting parallel group"/>
 <result pre="et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for" exact="chronic" post="HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88. 10.1056/NEJMoa1402355"/>
 <result pre="KowdleyKV, ZeuzemS, AgarwalK, et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for" exact="hepatitis" post="C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. 10.1056/NEJMoa1402869"/>
 <result pre="et al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for" exact="hepatitis" post="C in patients co-infected with HIV-1: a randomized trial."/>
 <result pre="30http://www.hepatitisc.uw.edu/page/treatment/drugs/ledipasvir-sofosbuvir. 31ChhatwalJ, KanwalF, RobertsMS, DunnMA. Cost-effectiveness and budget impact of" exact="hepatitis" post="C virus treatment with sofosbuvir and ledipasvir in the"/>
 <result pre="or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With" exact="Hepatitis" post="C in the Veterans Affairs National Healthcare System. Gastroenterology."/>
</results>
